Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

A McKesson business dedicated to leveraging oncology real-world evidence (RWE), clinical education, and provider technology to transform the fight against cancer, presented new data at the American Society of Clinical Oncology (ASCO) Annual Meeting which showed that 74 percent of patients with triple-negative breast…

Read MoreResearch Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

GE HealthCare Reimagining Better Health Study Identifies the Barriers to Achieving a More Human and Flexible Healthcare Experience

GE HealthCare, a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, today released Reimagining Better Health, a qualitative and quantitative study that amplifies the perspectives and needs of people at the center of healthcare — patients and clinicians.  The study aims…

Read MoreGE HealthCare Reimagining Better Health Study Identifies the Barriers to Achieving a More Human and Flexible Healthcare Experience

GE HealthCare Introduces Sonic DL: A Groundbreaking, FDA-Cleared AI Deep Learning Technology for Faster MRI

GE HealthCare today announced the FDA clearance and launch of Sonic DL – a state-of-the-art deep learning-based technology designed to dramatically accelerate image acquisition in magnetic resonance imaging (MRI). Sonic DL enables new imaging paradigms, such as high-quality cardiac MRI…

Read MoreGE HealthCare Introduces Sonic DL: A Groundbreaking, FDA-Cleared AI Deep Learning Technology for Faster MRI

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. Precision DL provides the image quality performance benefits typically…

Read MoreGE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

Cardinal Health today announced it has signed a definitive agreement to contribute its Outcomes™ business to Transaction Data Systems (TDS), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a minority stake in the combined entity. Under…

Read MoreCardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

Cardinal Health launches Modern Commerce Solutions for Retail Independent Pharmacies powered by Square

Cardinal Health (NYSE: CAH) today launched modern payment solutions, powered by Square, to help independent pharmacies increase operational efficiency, stay current with customer payment preferences, and access integrated software tools for their business. The collaboration with Square allows Cardinal Health to offer its…

Read MoreCardinal Health launches Modern Commerce Solutions for Retail Independent Pharmacies powered by Square

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

Today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment…

Read MorePfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV…

Read MoreU.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

fizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections…

Read MorePhase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

PropTech Company, Doormat, Raises $1.25 Million in Pre-Seed Funding, Revolutionizing a Critical Stage of the Homeownership Journey

Today, Doormat, Ontario’s real estate lawyer, enhancing the client experience and streamlining the legal process with advanced technology solutions, has announced it has raised $1.25M in pre-seed funding. Through this, Doormat is bringing much-needed simplicity and ease to the real estate…

Read MorePropTech Company, Doormat, Raises $1.25 Million in Pre-Seed Funding, Revolutionizing a Critical Stage of the Homeownership Journey